A Phase 3 interventional study of Ustekinumab in Crohn Disease, Colitis, Ulcerative and Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 48 sites in 13 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing ustekinumab in Crohn Disease — 3 open to participants now, 5 under way, 2 of them phase 3. Ustekinumab · Crohn Disease.
Among the 21 studies testing ustekinumab in Crohn Disease, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, and was the 17th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →3 of the 21 studies testing ustekinumab in Crohn Disease are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–70
By country, each count listing its studies:
Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 9 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 131 across the 21 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
63 studies in Crohn Disease by Johnson & Johnson: 16 open now, 23 under way, 10 of them phase 3. Of 38 finished, 16 (42%) have results posted.
Among the 63 studies in Crohn Disease by Johnson & Johnson, this one is the 22nd largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2021, is one of 23 in phase 3, reaches primary completion later than 6 of the 22 other live ones, and was the 41st registered.
Johnson & Johnson’s Crohn Disease studies by the year they started, since 1995.
3 of the studies testing ustekinumab in Crohn Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT06520397Sixth Affiliated Hospital, Sun Yat-sen UniversityEfficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | 2026-12-31 |
| NCT07303686McGill University Health Centre/Research Institute of the McGill University Health CentreDe-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing ustekinumab in Crohn Disease, from their registry updates:
Among Johnson & Johnson’s 63 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004, CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Participants enrolling from the Exposure Optimization Substudy may be eligible to remain on the every 4 weeks (q4w) dosing regimen.
Drug: Ustekinumab
Ustekinumab will be administered as a SC injection.
Also known as: STELARA
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
Time frame: Up to 6 years and 4 months
Number of Participants With Serious Adverse Events (SAEs)
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Up to 6 years and 4 months
Number of Participants with AEs Leading to Discontinuation of Study Intervention
Number of participants with AEs leading to discontinuation of study intervention will be reported.
Time frame: Up to 6 years and 4 months
Number of Participants with AEs of Interest
Number of participants with AEs of special interest (any newly identified malignancy case of active tuberculosis \[TB\], or opportunistic infection occurring after the first administration of study intervention\[s\]) will be reported.
Time frame: Up to 6 years and 4 months
Number of Participants with Abnormalities in Clinical Laboratory Parameters
Number of participants with abnormalities in clinical laboratory parameters (such as hematology and serum chemistry) will be reported.
Time frame: Up to 6 years and 4 months
Number of Participants with Injection-site Reactions
Number of participants with injection-site reactions will be reported. An injection-site reaction is any adverse reaction at a subcutaneous (SC) study intervention injection-site.
Time frame: Up to 6 years and 4 months
Number of Participants With AEs of Worsening of the Disease
Number of participants with AEs of worsening of the disease will be reported.
Time frame: Up to 6 years and 4 months
Number of Participants With Concomitant Therapy due to Loss of Response
Number of participants with concomitant therapy due to loss of response will be reported.
Time frame: Up to 6 years and 4 months
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Sep 2027, 71 months after the start.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 71 months is above that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ustekinumab
Janssen Research & Development, LLC →